Cost-effectiveness of extended-release methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder sub-optimally treated with immediate release methylphenidate.
Attention-Deficit/Hyperactivity Disorder (ADHD) is a common psychiatric disorder in children and adolescents. Immediate-release methylphenidate (IR-MPH) is the medical treatment of first choice. The necessity to use several IR-MPH tablets per day and associated potential social stigma at school ofte...
Main Authors: | Jurjen van der Schans, Nikos Kotsopoulos, Pieter J Hoekstra, Eelko Hak, Maarten J Postma |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4449164?pdf=render |
Similar Items
-
Methylphenidate extended-release oral suspension for the treatment of attention-deficit/hyperactivity disorder: a practical guide for pharmacists
by: Caballero J, et al.
Published: (2017-10-01) -
Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder
by: Hammerness Paul, et al.
Published: (2007-09-01) -
Modified-release methylphenidate-induced Raynaud’s phenomenon in an adolescent with attention deficit hyperactivity disorder
by: Ali Karayağmurlu, et al.
Published: (2022-09-01) -
Evaluation of acute cardiovascular effects of immediate-release methylphenidate in children and adolescents with attention-deficit hyperactivity disorder
by: Lamberti M, et al.
Published: (2015-05-01) -
Clinical use of a modified release methylphenidate in the treatment of childhood attention deficit hyperactivity disorder
by: Takon Inyang
Published: (2011-09-01)